Tagged with GE

Abnova Chairman of Abnova Corporation Wilber Huang discusses the company’s core strengths, Taiwan’s bilateral relationship with China’s biotech industry, and offers some advice to future start-up biotech companies in Taiwan. Abnova was founded during a very exciting time in the biotech industry. Can you tell us a bit more about what…

Bionet Corp. The chairman of Bionet reflects on past market challenges and the growing strength of Bionet’s reach both domestically and globally, and why Taiwan is the perfect size for a biotech start-up, despite its strict regulatory environment. Bionet is a cord blood banking pioneer in Taiwan. What is the story of…

Biosimilars Jim Keon, Preisdent of CGPA, discusses the cost-saving benefits that generic drugs have offered Canada, and offers his insights into Canada’s intellectual property regime and the challenges of pricing in Canada. As a privileged witness to the evolution of the Canadian generic industry, what have been some of the defining…

Medicines Country Manager of Norpharma, Denmark, discusses how the company has been able to remain a market competitor while maintaining satisfactory payer prices. Since Norpharma’s founding in 1192, what are some of its key areas and products? We work in a number of strategic areas; pain management is where our heritage…

Financial Management YFY Biotech Management Company has not always been involved in the biotech sector. How has it evolved over the years? Yuen Foong Yu Group originally began as a paper mill company, which grew alongside Taiwan as the country moved from agriculture to industry. In moving away from its traditional business…

Generics Dr. Chen, you joined US-based Anchen Pharmaceuticals in 2009 to help the company form a spin-off in Taiwan. Why did a US-based company look to establish itself in Taiwan, and then export back to the US? In my view, the US is not a very attractive environment for a company…

GCB Mr. Lin, you enjoyed a decades-long career in the ICT industry before making the transition to healthcare. What can you tell our readers about the evolution of General Biologics Corp. under your leadership? GBC was established in 1984. Government shareholders held 70 percent ownership, with the remaining 30 percent distributed…

Aspen Labs Marked socio-economic differences in Mexico are playing an important role in pushing the uptake of generics, and these issues are starting to affect multinational corporations (MNCs). MNCs are being forced to open up and diversify, quite simply to have their fingers in as many pies where they can compete successfully.…

Generics The president & CEO of Canada’s largest generics player considers the current market dynamics for generic products, including IP regulation, generic penetration, and the advantages of balancing branded and non-branded products.  What was the strategy behind the integration of Novopharm into Teva? Novopharm is one of the pioneers in the…

Clinical trials TaiGen is on the brink of releasing Taiwan’s first innovative drug. In this interview, the Chairman and CEO of the company discusses the development path the company chose to take, and explains the decision to market the drug first in China. Nemonoxacin will be the first-ever pharmaceutical developed in this…

Generics In the first part of this two-part interview, the Chairman of TTY Biopharm considers the success of his long-term strategy to streamline TTY’s portfolio and focus on the company’s strengths, and talks about the opportunities in Asia for companies that have followed a similar path to TTY. To read the…

Clinical trials The President & CEO of Vita Genomics talks about the advantages that genomic testing offer both to sick and healthy patients, as well as the opportunities to catalogue the science behind Traditional Chinese Medicine. What is the vision behind Vita Genomics? Vita Genomics was founded in 2001. At the time,…